home / stock / achv / achv news

ACHV News and Press, Achieve Life Sciences Inc. From 06/29/22

Stock Information
Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com
Menu
ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...
ACHV - Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation

SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced...
ACHV - Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference

SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today ...

ACHV - Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users

SEATTLE and VANCOUVER, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today ...

ACHV - Achieve Life Sciences Announces Participation at LD Micro Invitational Conference

SEATTLE and VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announ...
ACHV - Achieve Life Sciences (ACHV) Investor Presentation - Slideshow

The following slide deck was published by Achieve Life Sciences, Inc. in conjunction with this event. For further details see: Achieve Life Sciences (ACHV) Investor Presentation - Slideshow

ACHV - 36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16 th - 20 th , 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Spring in...

ACHV - Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference

SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announ...
ACHV - Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript

Achieve Life Sciences, Inc. (ACHV) Q1 2022 Earnings Conference Call May 12, 2022, 16:30 ET Company Participants John Bencich - CEO & Director Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer Conference Call Participants Thomas Flaten ...

ACHV - Achieve Life Sciences GAAP EPS of -$0.80 in-line

Achieve Life Sciences press release (NASDAQ:ACHV): Q1 GAAP EPS of -$0.80 in-line. As of March 31, 2022, the company’s cash, cash equivalents, and restricted cash was $36.4 million. For further details see: Achieve Life Sciences GAAP EPS of -$0.80 in-line

ACHV - Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update

SEATTLE and VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announ...
Previous 10 Next 10